MacroGenics to Participate in Upcoming Investor Conferences
February 3, 2022 ...
Bloom Energy to Announce Fourth Quarter 2021 Financial Results and Outlook on February 10, 2022
SAN JOSE, Calif., January 25, 2022 — Bloom Energy (NYSE: BE) today announced it will release its fourth quarter and fiscal year 2021 financial results on February 10, 2022 after market close. Bloom Energy’s management will host a conference call at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET) on the same day to discuss these results and the longer term outlook for the company. ...
DataBridge Sites is excited to announce our strategic partnership with Reliant Management
The collaboration will provide our companies the ability to offer unique infrastructure services in emerging technologies and the regulated government space. The alliance brings DataBridge and Reliant to the forefront in offering: ...
REAK (Germany) and Assured Valuations (Australia) Join the FON Global Alliance
Increasing clients’ opportunities for cross-border investments ...
What are the Maryland Office of Statewide Broadband’s priorities for 2022?
At the Maryland Tech Council’s virtual Advocacy Summit, Director Kenrick Gordon gave insight on the state’s plans for broadband infrastructure. ...
Anne Arundel Economic Development: VOLT Growth Fund
The VOLT Growth Fund (VGF) aims to help Maryland based high growth innovative and technology product companies implement a go-to-market strategy and accelerate sales. The program has flexible underwriting standards and payment terms to allow a company to grow its revenue and workforce as well as facilitate future equity investment. ...
Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine
The Novavax vaccine would be the first protein-based alternative available in Israel ...
Pandemic Preparedness: The next best time to act is now
By: Robert G. Kramer, CEO, Emergent – ...
QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance
Published: Jan 25, 2022 ...
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains
GAITHERSBURG, Md., Feb. 1, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a request to the U.S Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for immunization of individuals 18 year of age and older against SARS-CoV-2. ...